Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
about
Multimodality Imaging in CardiooncologyUse of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in KoreaManagement of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Treating venous thromboembolism in patients with cancer.Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Antithrombotic therapy and platelet transfusions in hematologic malignancy patients presenting chemotherapy-induced thrombocytopenia: a French survey.Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases.Lenalidomide in multiple myeloma-a practice guideline.Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Pulmonary hypertension complicating multiple myeloma.Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma.The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical MethodologiesThalidomide for inflammatory bowel disease: Systematic review.The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.Latest advances and current challenges in the treatment of multiple myeloma.Thrombosis in multiple myeloma (MM).Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence.Emerging biological insights and novel treatment strategies in multiple myeloma.Coagulation and cancer: biological and clinical aspects.Perspectives in the treatment of multiple myeloma.Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist.Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective.Thromboembolic risk in hematological malignancies.Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.An update on the use of lenalidomide for the treatment of multiple myeloma.A review of the venous thrombotic issues associated with multiple myeloma.Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.Prevention and treatment of venous thromboembolism in patients with cancer.Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer.Comprehensive review of cardiovascular toxicity of drugs and related agents.Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma.Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs.Retrospective study of the incidence and patterns of arterial and venous thrombosis in Chinese versus African American patients with multiple myeloma.Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
P2860
Q26795452-BC9A0ABB-2587-4809-9C64-0CD525C4F4FFQ26992002-CD7D13E4-C353-452C-9D36-A4B0437E6F29Q30417015-E260C155-A04D-42E1-9A4C-568C642F6ECFQ33398180-1BDBFFDE-DD23-47B0-8C89-AB35CA429A87Q33400564-855A9185-7318-494E-8BB3-DCBC97BB486AQ33404007-503799E5-7A6C-4575-8C35-4913B54125BFQ33441333-BF40A4A9-35A6-411A-BC73-E31B8224326EQ33932989-8883DD7C-BAC1-4CA8-AB71-FF72FD9FE55AQ34656086-20B4A6C3-8927-492D-A282-14FF1D85F6F9Q35171777-D963BADD-3B48-469D-8F07-9CD12CDD7B73Q36016552-79F2B5A3-AEC6-4EDB-A5CC-7C72A0CAC2BCQ36229918-382AE117-ABD5-4ADF-94C4-0530DEF57A8FQ36612613-56C1668F-F9A3-40A6-AA51-3546E9F7E1C0Q37069353-F93E648E-3330-4B98-8588-12D6DBD8E148Q37605607-7A065B01-0E57-430D-B39A-A104CD609F8DQ37644252-AFE417B8-560B-4920-A71A-73060A522EC8Q37986287-8DAE6DE5-2B1C-40DC-9ED1-CAA4715C5970Q38003019-6B63A2DE-3D54-4C9B-B05A-C91A5DBDF653Q38035031-765BA78B-515F-4318-AA43-1278CBA4AAEFQ38037600-5CD0A7C5-1687-400D-A303-34BA8E075438Q38070918-3892785D-8C84-49ED-B2AC-2753380F829EQ38108391-4F0AF1EC-D206-466A-AB8E-593B95D1062EQ38111390-CA7EEF38-4CC4-4AB9-9547-BAF2B555BF2EQ38216650-EA5DDD96-DFE6-497C-9EB8-E673D58E3DCDQ38287304-79CD7FEC-5DAB-4328-86CC-6620EE185806Q38446990-6211B64C-A6B2-4655-89B0-B2B02A8E2AD0Q38545607-9F18A4D1-A9F1-48F8-9B4B-0F914F987699Q38845946-C0572758-5C40-49F9-BC44-9717C9B32E3FQ39909234-B2913AA0-329F-4513-A6A0-585D123915E3Q41877145-A51F8050-D805-4D16-B74C-F684FB5A80E6Q43213080-C42D79FC-4805-4FB5-B3DE-4F856E34E244Q45073137-C123EBF7-D02E-48A2-9FBC-044099A3A51CQ47400340-E34019B7-7558-428C-846C-177EAD8FCD17Q47556269-937C37EB-2958-4AEB-86DD-FF54B8E2DF35Q48235838-B5299E02-D78B-45DE-9E50-E6C6202B01D8Q50197484-D6C72C44-25FF-4CEF-8146-8947C7DC0E98Q53079455-FE0F6F21-0BCD-4423-80C0-1C2D246DDFB3Q53774591-DF4C1F79-662A-4B38-A8B1-8351B638F2CCQ56362782-606E5C97-0A9B-4418-A450-27B618DD805F
P2860
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rates of venous thromboembolis ...... atic review and meta-analysis.
@en
Rates of venous thromboembolis ...... atic review and meta-analysis.
@nl
type
label
Rates of venous thromboembolis ...... atic review and meta-analysis.
@en
Rates of venous thromboembolis ...... atic review and meta-analysis.
@nl
prefLabel
Rates of venous thromboembolis ...... atic review and meta-analysis.
@en
Rates of venous thromboembolis ...... atic review and meta-analysis.
@nl
P2093
P2860
P921
P1476
Rates of venous thromboembolis ...... matic review and meta-analysis
@en
P2093
P2860
P304
P356
10.1111/J.1538-7836.2011.04215.X
P577
2011-04-01T00:00:00Z